Records containing: Multiple Sclerosis, Relapsing-Remitting
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2024-06-12A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing (EID) of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment - Followed by an Open-Label Crossover Extension Study Comprising Subcutaneous and Intravenous Natalizumab Administration
-
CLINICAL_TRIALS study record update · 2024-06-11A Multicenter Observational Study for Ex-vivo Evaluation of the Likelihood of Response to an Experimental Tolerance Restoration Therapy in Subjects Diagnosed With Multiple Sclerosis (MS)
-
CLINICAL_TRIALS study record update · 2024-05-08Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA/Tonalin® FFA 80) and Probiotics (Vivomixx®/VSL#3) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2024-03-22EXPOSITION (EXPosome, Oxidative Stress and InflammaTION) in Persons With Multiple Sclerosis Study
-
CLINICAL_TRIALS study record update · 2024-03-12Targeting Subclinical Motor and Cognitive Impairment in Patients With Early Onset Multiple Sclerosis at High Risk of disEase Acitivity Through a Preventive personaLised and InnovAtive rehaBiLitation stratEgy. (RELIABLE)
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2024-03-08A Phase I/II Dose Escalation/Adaptive Design Study to Evaluate the Safety and Efficacy of IMCY-0141 in Patients With Relapsing Remitting-Multiple Sclerosis (RR-MS)
-
CLINICAL_TRIALS study record update · 2024-03-07Efficacy of EGb 761® 120mg Twice a Day Versus Placebo on Cognitive Impairment in Patients With Multiple Sclerosis. A Randomised, Double-blind, Multicentre, Parallel Groups Placebo Controlled Phase III Study.
-
CLINICAL_TRIALS study record update · 2024-03-01An Examination of Cognitive Fatigue Using Functional Neuroimaging
-
CLINICAL_TRIALS study record update · 2024-02-15Biomarker for Cognitive Fatigue Using Functional Imaging in Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2024-02-15Evaluating Task-Oriented Exercise Effects on Walking Function and the Central Nervous System in People With Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2024-02-14A Biomarker for Cognitive Fatigue Using Functional Imaging in MS
-
CLINICAL_TRIALS study record update · 2024-02-06Investigating the Longitudinal Relationships Between Visual Pathway Injury, Radiological and Blood Biomarkers in Multiple Sclerosis and Related Disorders
-
CLINICAL_TRIALS study record update · 2024-01-08Identifying Immune Biomarkers of Disease and Disease Control in Autoimmune Neurological Disease Using Autologous Haematopoietic Stem Cell Transplantation
-
CLINICAL_TRIALS study record update · 2024-01-08Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients
-
CLINICAL_TRIALS study record update · 2024-01-03Innovative Protocol Targeting Cognitive Dysfunction in Multiple Sclerosis: tDCS to Enhance Cognitive Training in a Randomized, Double-blind, Controlled, Exploratory Pilot Study
-
CLINICAL_TRIALS study record update · 2024-01-03Understanding Magnetic Resonance Imaging in Multiple Sclerosis - a Randomized, Controlled, Double Blind Trial
-
CLINICAL_TRIALS study record update · 2023-12-05Multiparametric Clinical, Radiological, Neuropsychological, and Neurophysiological Assessment to Investigate Prognostic Factors for Disease Evolution and Treatment Response in MS: a Prospective Study.
-
CLINICAL_TRIALS study record update · 2023-12-01A Phase III Study in Subjects With Relapsing Forms of Multiple Sclerosis (RMS) to Asses Efficacy, Safety and Tolerability of GA Depot, a Long Acting IM Injection of Glatiramer Acetate, Once Monthly Compared to Placebo
-
CLINICAL_TRIALS study record update · 2023-11-22Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden - a Register-based Retrospective Observational Study
-
CLINICAL_TRIALS study record update · 2023-11-09Efficacy and Safety of OCH-NCNP1 in Patients With Relapsing Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2023-11-09Optimal Conditioning Regimen Protocol for Autologous Hematopoietic Stem Cell Transplantation of Relapsing Remitting Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2023-10-23A Retrospective Analysis in Real World on Lymphocyte Reconstitution After Lymphopenia in Patients Treated by Tecfidera and Description of Management Strategies in France
-
CLINICAL_TRIALS study record update · 2023-09-29Effect of Computerized Cognitive Training in Persons With MS
-
CLINICAL_TRIALS study record update · 2023-09-13Development and Evaluation of an Interactive Web-based Programme on Relapse Management for People With Multiple Sclerosis - a Randomized Controlled Trial With Mixed Methods Process Evaluation
-
CLINICAL_TRIALS study record update · 2023-09-07Prospective Single Centre Trial of Percutaneous Tibial Nerve Stimulation With the Implantable StimRouter Neuromodulation System for the Treatment of Refractory Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis